We asked some of our speakers who will be taking part in this year’s inaugural meeting – ARDS Summit.
As a speaker, how do you expect ARDS drug development to evolve in 2021 and why are you excited to be involved with the ARDS Drug Development Summit?
Increasing move to develop a precision medicine approach to accelerate new treatments for ARDS and participating in the discussions around this.
Danny McAuley, Queen University Belfast
ARDS has been eluding us for decades. Big steps have been taken during the past year to come up with new innovative drugs to concur ARDS. I cannot wait to see what the future brings us.
Juho Jalkanen, Faron Pharmaceuticals
Drug development had not progressed in ARDS in recent past. Unfortunately, due to the events of the past year, we all have turned our attention back towards ARDS and this is hopeful for patients who experience this condition and have so few therapeutic options.
Nina Patel, Boehringer Ingelheim
We need to come together as a scientific community to share our key research questions and answers so we can expedite drug development for patients with an extremely high unmet need. The summit will provide a framework to accelerate our efforts.
Shamsah Kazani, Alexion Pharmaceuticals